Dexrazoxane (ICRF-187) - A cardioprotectant and modulator of action of some anticancer drugs;Deksrazoksan (ICRF-187) - czynnik kardioochronny i modulator działania niektórych leków przeciwnowotworowych

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 584-590

  Kik, Krzysztof ^a   Szmigiero, Leszek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anthracycline; Apoptosis; Cardiac toxixity; Dexrazoxane; ICRF 187; Topoisomerase II

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; CARDIOVASCULAR AGENT; CHELATING AGENT; RAZOXANE;

CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; CHEMISTRY; NEOPLASM; REVIEW;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; CHELATING AGENTS; NEOPLASMS; RAZOXANE;

EID: 39049191506     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Bernitsas E., Wei W., Mikol D.D.: Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann. Neurol., 2006; 59: 206-209
2. Buss J.L., Hasinoff B.B.: Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187). Arch. Biochem. Biophys., 1995; 317: 121-127
3. Chen A.Y., Liu L.F.: DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 1994; 34: 191-218
4. Ciesielska E., Studzian K., Wąsowska M., Oszczapowicz I., Szmigiero L.: Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety. Cell Biol. Toxicol., 2005; 21: 139-147
5. Classen S., Olland S., Berger J.M.: Structure of the topoismerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc. Natl. Acad. Sci. USA, 2003; 100: 10629-10634
6. Cocker H.A., Tiffin N., Pritchard-Jones, K., Pinkerton C.R., Kelland L.R. In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin. Cancer Res., 2001; 7: 3193-3198
7. Cvetkovic R.S., Scott L.J.: Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy. Drugs, 2005; 65: 1005-1024
8. Doroshow J.H., Locker G.Y., Myers C.E.: Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J. Clin. Invest., 1980; 65: 128-135
9. Dudka J.: Rola reaktywnych form tlenu I azotu w zaburzeniach komórkowej homeostazy wapnia I zelaza w kardiotoksycznosci antracyklinowej. Post. Hig. Med. Dosw., 2006; 60: 241-247
10. Elliott P.: Pathogenesis of cardiotoxicity induced by anthracyclines. Semin. Oncol., 2006; 33: 2-7
11. Erlaky H., Toth K., Szabolcs J., Horvath E., Kemeny V., Muller J., Csoka M., Jokuti L., Erdelyi D., Kovacs G.: Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect? Magy. Onkol., 2006; 50: 25-32
12. Hasinoff B.B.: An HPLC and spectrometric study of the hydrolysis of ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane) and its open ring hydrolysis intermediates. Int. J. Pharmacol., 1994; 107: 67-76
13. Hasinoff B.B.: Dexrazoxane use in the prevention of anthracycline extravasation injury. Future Oncol., 2006: 2: 15-20
14. Hasinoff B.B.: Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab. Dispos., 1993; 21: 883-888
15. Hasinoff B.B.: The interaction of the cardioprotective agent ICRF-187[+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions, 1989; 26: 378-385
16. Hasinoff B.B., Abram M.E., Barnabe N., Khelifa T., Allan W.P., Yalowich J.C.: The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol. Pharmacol., 2001; 59: 453-461
17. Hasinoff B.B., Davey J.P., O'Brien P.J.: The Adriamycin (doxorubicin)-induced inactivation of cytochrome c oxidase depends on the presence of iron or copper. Xenobiotica, 1989; 19: 231-241
18. Hasinoff B.B., Kala S.V.: The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187[(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925. Agents Actions, 1993; 39: 72-81
19. Hasinoff B.B., Reinders F.X., Clark V.: The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. Drug Metab. Dispos., 1991; 19: 74-80
20. Hasinoff B.B., Schnabl K.L., Marusak R.A., Patel D., Huebner E.: Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc. Toxicol., 2003; 3: 89-99
21. Hasinoff B.B., Schroeder P.E., Patel D.: The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol. Pharmacol., 2003: 64: 670-678
22. Holm B., Sehested M., Jensen P.B.: Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin. Cancer Res., 1998; 4: 1367-1373
23. Hsiang Y.H., Liu L.F.: Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. J. Biol. Chem., 1989; 264: 9713-9715
24. Jensen L.H., Dejligbjerg M., Hansen L.T., Grauslund M., Jensen P.B., Sehested M.: Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells. BMC Pharmacol., 2004; 4: 31
25. Khelifa T., Beck W.T.: Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal Kinase 1 (JNK1) activation in VM-26 resistant CEM cells. Biochem. Pharmacol., 1999; 58: 1247-1257
26. Larsen A.K., Escargueil A.E., Skladanowski A.: Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther., 2003; 99: 167-181
27. acko A., Wlodarska I., Zymliñski R., Mazur G., Wróbel T., Gisterek I.: Kardiotoksycznosæ leczenia przeciwnowotworowego. Pol. Merkuriusz Lek., 2002; 13: 79-85
28. Marty M., Espie M., Llombart A., Monnier A., Rapoport B.L., Stahalova V.: Dexrazoxane Study Group. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracyclinebased chemotherapy. Ann. Oncol., 2006; 17: 614-622
29. Nitiss J.L., Beck W.T.: Antitopoisomerase drug action and resistance. Eur. J. Cancer, 1996; 32A: 958-966
30. Pastwa E., Ciesielska E., Piestrzeniewicz M.K., Denny W.A., Gniazdowski M., Szmigiero L.: Cytotoxic and DNA-damaging properties of N-2-(dimethylamino)ethyl acridine-4-carboxamide (DACA) and its analogues. Biochem. Pharmacol., 1998; 56: 351-359
31. Sargent J.M., Williamson C.J., Yardley C., Taylor C.G., Hellmann K.: Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukemia line, K562. Br. J. Cancer, 2001; 84: 959-964
32. Schroeder P.E., Wang G.Q., Burczynski F.J., Hasinoff B.B.: Metabolism of the cardioprotective drug and one of its metabolites by isolated rat myocytes, hepatocytes, and blood. Drug Metab. Dispos., 2005; 33: 719-725
33. Schroeder P.E., Davidson J.N., Hasinoff B.B.: Dihydroortase catalyzes the ring opening of the hydrolisis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab. Dispos., 2002; 30: 1431-1435
34. Schroeder P.E., Hasinoff B.B.: Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metalchelating form in the rat. Drug Metab. Dispos., 2005; 33: 1367-1372
35. Schuchter L.M., Hensley M.L., Meropol N.J., Winer E.P.: American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol., 2002; 20: 2895-2903
36. Stryer L.: Fosforylacja oksydacyjna. W: Biochemia, PWN Warszawa 2000: 564-592
37. Swain S.M., Whaley F.S., Gerber M.C., Ewer M.S. Bianchine J.R., Gams.R.A.: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol., 1997; 15: 1333-1340
38. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., Jones S.E., Wadler S., Desai A., Vogel C., Speyer J., Mittelman A., Reddy S., Pendergrass K., Velez-Garcia E., Ewer M.S., Bianchine J.R., Gams R.A.: Cardioprotection with dexrazoxane for doxorubicincontaining therapy in advanced breast cancer. J. Clin. Oncol., 1997; 15: 1318-1332
39. Szulawska A., Czyz M.: Molekularne mechanizmy dzialania antracyklin. Post. Hig. Med. Dosw., 2006; 60: 78-100
40. Uemura T., Ohkura H., Adachi Y., Morino K., Shiozaki K., Yanagida M.: DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. Pombe. Cell, 1987; 50: 917-925
41. Van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C.: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev., 2005; 25: CD003917
42. Venturini M., Michelotti A., Del Mastro L., Gallo L., Carnino F., Garrone O., Tibaldi C., Molea N., Bellina R.C., Pronzato P., Cyrus P., Vinke J., Testore F., GuelfiM., Lionetto R., Bruzzi P., Conte P.F., Rosso R.: Multicenter randomized controlled clinical trials to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J. Clin. Oncol., 1996; 14: 3112-3120
43. Warburton P.E., Cooke C.A., Bourassa S., Vafa O., Sullivan B.A., Stetten G., Gimelli G., Warburton D., Tyler-Smith C., Sullivan K.F., Poirier G.G., Earnshaw W.C.: Immunolocalization of CENP-A suggests a distinct nucleosome structure at the inner kinetochore plate of active centromeres. Curr. Biol., 1997; 7: 901-904
44. Wessel I., Jensen L.H., Jensen P.B., Falck J., Rose A., Roerth M., Nitiss J.L., Sehesed M.: Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoizomeraze II catalitic inhibitor ICRF-187 demonstrae a functional R162Q mutation in the walker a consensus ATP binding domain of the a isoform. Cancer Res., 1999; 59: 3442-3450
45. Wouters K.A., Kremer L.C., Miller T.L., Herman E.H., Lipshultz S.E.: Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. Br. J. Haematol., 2005; 131: 561-578